University Hospitals (UH) Case Medical is now offering a new, non-invasive test for coronary artery disease designed to help physicians develop the right treatment plan for each patient. Developed by HeartFlow Inc., computed tomography-fractional flow reserve (CT-FFR) is a non-invasive imaging technology specifically designed to offer insight on both the extent of the blockage, as well as whether it is impacting blood flow to the heart. UH Case Medical Center’s Daniel Simon, M.D., will be first to use the CT-FFR test in the United States.

For lung cancer that cannot be removed with surgery, radiotherapy is the primary treatment option. However, it is associated with a range of side effects, including fatigue and inflammation of the esophagus and lungs. Current methods to record lung-cancer treatment-related toxicities rely on assessment by healthcare professionals. Now a team from The University of Manchester and The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Center — has explored the use of patient-reported outcomes to improve the recording of side effects for lung cancer patients.